<TABLE>
Cancer
             $        $         %         $           $                  %
Breast*      90610    8489      9.37      82121       130909    0.5941   17.4    0.1034
Breast       38130    4330      11.35     33801       60861     0.8006   16      0.1281
Prostate     28275    1770      6.26      26505       37566     0.4173   16      0.0668
Lung         82897    20787     25.08     62110       90201     0.4523   74      0.3347
Colorectal   75170    16623     22.11     58546       94684     0.6172   46      0.2839
Melanoma     12541    5085      40.55     7456        40691     4.4573   15.3    0.682
</TABLE>
<TEXT>
Table 10. The quantities in columns 2-9 are defined in Subsection 6.1. Row 2 corresponds to the commercial claims data of [Blumen et al, 2016]. Rows 3-6 correspond to the Medicare data of [Schrag, 2015]. Row 7 corresponds to the data reported in [Styperek and Kimball, 2012].
</TEXT>
<TABLE>
Cancer        Estimated     SD, %   Estimated      Estimated                                Estimated
              National              New Cases in   Per-new-                %       %        National
              Spending in           2017,          incidence                                Cost-
              2017, $M              #              Spending in                              savings,
                                                   2017, $                                  $M
All Sites     152901.1      8.49    1688780        90539        ---        ---     ---      25902
Bladder       4543.33       6.41    79030          57489        0.5202     12.42   6.07     276
Brain         5604.18       11.58   23800          235470       0.5232     39.94   17.28    968
Breast        19478.58      7.81    252710         77079        0.5941     17.4    9.37     1562
Cervix        1441.05       10.69   12820          112406       0.5232     34.71   15.37    221
Colorectal    15727.4       9.29    135430         116129       0.6172     46      22.11    3477
Esophagus     1857.85       15.09   16940          109672       0.5232     60.99   24.19    449
Oral          4101.55       9.34    49670          82576        0.5232     62.41   24.62    1010
Kidney        5487.4        13.12   63990          85754        0.5232     33.36   14.86    815
Leukemia      6772.22       8.72    62130          109001       0.5232     39.94   17.28    1170
Lung          13693.22      11.31   222500         61543        0.4523     74      25.08    3434
Lymphoma      15096.07      8.76    80500          187529       0.5232     39.94   17.28    2609
Melanoma      3308.32       10.28   87110          37979        4.4573     15.3    40.55    1342
Ovary         5338.73       11.32   22440          237911       0.5232     61.89   24.46    1306
Pancreas      3040.12       16.06   53670          56645        0.5232     66.45   25.8     784
Prostate      14873.72      5.47    161360         92177        0.4173     16      6.26     931
Stomach       2074.28       11.88   28000          74081        0.5232     60.56   24.06    499
Uterus        2947.42       9.08    61380          48019        0.5232     21.14   9.96     294
Other         27515.67      10.11   275300         99948        0.5232     39.94   17.28    4755
</TABLE>
<TEXT>
Table 11. Cancer site abbreviations in column 1 are the same as in Table 3. Column 2 = mean estimated spending based on [NCI, 2017b] (which uses the “head-and-neck” nomenclature for Oral = oral cavity and pharynx cancer), and column 3 = standard deviation (see Subsection 6.2). Column 4 = number of estimated new incidences as reported in [ACS, 2017] and [Siegel et al, 2017]. Column 5 = estimated per-new-incidence spending. The factors (column 6) and rate (column 7) are taken from Table 10 for breast, colorectal, lung and prostate cancers and melanoma (bold font). For other cancer sites the factor is extrapolated from the values in Table 10 (italicized font) and rate is taken from Table 3 (regular font) or extrapolated therefrom (italicized font). See Subsection 6.1. The relative cost-savings (column 8) are obtained via Eq. (12) and Eq. (13), and cost-savings from early diagnosis (column 9) via Eq. (15), where the factor is set to 1 for all cancer sites except breast cancer, for which .
</TEXT>
<PAGE_FOOTER>
22
</PAGE_FOOTER>
<PAGE_BREAK>
